124 related articles for article (PubMed ID: 20679350)
1. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
5. Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.
Zhao W; Yang Z; Liu X; Tian Q; Lv Y; Liang Y; Li C; Gao X; Chen L
J Int Med Res; 2013 Jun; 41(3):573-83. PubMed ID: 23613495
[TBL] [Abstract][Full Text] [Related]
6. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
7. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
8. Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
Umekawa K; Kimura T; Kudoh S; Suzumura T; Nagata M; Mitsuoka S; Matsuura K; Oka T; Yoshimura N; Kira Y; Hirata K
Osaka City Med J; 2013 Jun; 59(1):53-60. PubMed ID: 23909081
[TBL] [Abstract][Full Text] [Related]
9. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.
Wang S; Han X; Hu X; Wang X; Zhao L; Tang L; Feng Y; Wu D; Sun Y; Shi Y
Clin Chim Acta; 2014 Mar; 430():63-70. PubMed ID: 24378285
[TBL] [Abstract][Full Text] [Related]
11. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
12. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs.
Tanaka H; Kimura T; Kudoh S; Mitsuoka S; Watanabe T; Suzumura T; Tachibana K; Noguchi M; Yano S; Hirata K
Int J Cancer; 2011 Sep; 129(6):1410-6. PubMed ID: 21128242
[TBL] [Abstract][Full Text] [Related]
13. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
Kotsakis A; Georgoulias V
Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
[TBL] [Abstract][Full Text] [Related]
14. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Nishio M; Yamanaka T; Matsumoto K; Kimura H; Sakai K; Sakai A; Sone T; Horiike A; Koizumi F; Kasahara K; Ohira T; Ikeda N; Saijo N; Arao T; Nishio K
J Thorac Oncol; 2011 Nov; 6(11):1889-94. PubMed ID: 21964526
[TBL] [Abstract][Full Text] [Related]
15. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
da Cunha Santos G; Saieg MA; Geddie W; Leighl N
Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
[TBL] [Abstract][Full Text] [Related]
16. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.
Vollebergh MA; Kappers I; Klomp HM; Buning-Kager JC; Korse CM; Hauptmann M; de Visser KE; van den Heuvel MM; Linn SC
J Thorac Oncol; 2010 Dec; 5(12):1939-48. PubMed ID: 21102259
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutation in gastric cancer.
Liu Z; Liu L; Li M; Wang Z; Feng L; Zhang Q; Cheng S; Lu S
Pathology; 2011 Apr; 43(3):234-8. PubMed ID: 21436633
[TBL] [Abstract][Full Text] [Related]
18. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.
Shukuya T; Takahashi T; Naito T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Murakami H; Harada H; Mitsuya K; Endo M; Nakasu Y; Takahashi K; Yamamoto N
Lung Cancer; 2011 Dec; 74(3):457-61. PubMed ID: 21571388
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Umeguchi H; Sueoka-Aragane N; Kobayashi N; Nakamura T; Sato A; Takeda Y; Hayashi S; Sueoka E; Kimura S
Oncol Rep; 2015 Jan; 33(1):391-6. PubMed ID: 25338771
[TBL] [Abstract][Full Text] [Related]
20. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
